Background: In patients with peripheral arterial disease (PAD), walking improvements are often limited by early pain onset due to vascular claudication. It would thus appear interesting to develop noninvasive therapeutic strategies, such as transcutaneous electrical nerve stimulation (TENS), to improve the participation of PAD patients in rehabilitation programmes, and thus improve their quality of life. Our team recently tested the efficacy of a single 45-min session of 10-Hz TENS prior to walking. TENS significantly delayed pain onset and increased the pain-free walking distance in patients with class-II PAD. We now seek to assess the efficacy of a chronic intervention that includes the daily use of TENS for 3 weeks (5 days a week) on walking distance in Leriche-Fontaine stage-II PAD patients.

Methods/design: This is a prospective, double-blind, multicentre, randomised, placebo-controlled trial. One hundred subjects with unilateral PAD (Leriche-Fontaine stage II) will be randomised into two groups (1:1). For the experimental group (TENS group): the treatment will consist of stimulation of the affected leg (at a biphasic frequency of 10 Hz, with a pulse width of 200 μs, maximal intensity below the motor threshold) for 45 min per day, in the morning before the exercise rehabilitation programme, for 3 weeks, 5 days per week. For the control group (SHAM group): the placebo stimulation will be delivered according to the same modalities as for the TENS group but with a voltage level automatically falling to zero after 10 s of stimulation. First outcome: walking distance without pain.

Secondary Outcomes: transcutaneous oxygen pressure (TcPO) measured during a Strandness exercise test, peak oxygen uptake (VO peak), endothelial function (EndoPAT®), Ankle-brachial Pressure Index, Body Mass Index, lipid profile (LDL-C, HDL-C, triglycerides), fasting glycaemia, HbA1c level, and the WELCH questionnaire.

Discussion: TENS-PAD is the first randomised controlled trial that uses transcutaneous electrical therapy as an adjuvant technique to improve vascular function in the treatment of PAD. If the results are confirmed, this technique could be incorporated into the routine care in cardiovascular rehabilitation centers and used in the long term by patients to improve their walking capacity.

Trial Registration: ClinicalTrials.gov, ID: NCT02678403 . Registered on 9 February 2016.

Sponsor: Toulouse University Hospital.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553808PMC
http://dx.doi.org/10.1186/s13063-017-1997-1DOI Listing

Publication Analysis

Top Keywords

walking distance
16
transcutaneous electrical
12
electrical nerve
8
nerve stimulation
8
distance patients
8
patients peripheral
8
peripheral arterial
8
arterial disease
8
randomised controlled
8
controlled trial
8

Similar Publications

Background: Based on explainable DenseNet model, the therapeutic effects of optimization nursing on patients with acute left heart failure (ALHF) and its application values were discussed.

Method: In this study, 96 patients with ALHF in the emergency department of the Affiliated Hospital of Xuzhou Medical University were selected. According to different nursing methods, they were divided into conventional group and optimization group.

View Article and Find Full Text PDF

Older adults are vulnerable to heat-related morbidity and mortality due to reduced thermoregulatory function associated with aging. The aim of this study was to examine the relationship between age and thermoregulatory behaviour during walking exercise in Control (22 °C; 40% relative humidity [RH]) and Hot (35 °C, 40% RH) conditions. Thirty-six healthy males (age 46 ± 20 (range 19-86) years; stature 177 ± 7 cm; body mass 75.

View Article and Find Full Text PDF

Comparative breakthrough: Umbilical cord mesenchymal stem cells bone marrow mesenchymal stem cells in heart failure treatment.

World J Cardiol

December 2024

Department of Geriatics, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.

In this article, we evaluate the comparative efficacy and safety of mesenchymal stem cells (MSCs) derived from bone marrow (BM-MSCs) and umbilical cord (UC-MSCs) in the treatment of heart failure and myocardial infarction. MSCs have gained importance as living bio drug due to their regenerative potential, with BM-MSCs being the most extensively studied. However, UC-MSCs offer unique advantages, such as noninvasive collection and fewer ethical concerns.

View Article and Find Full Text PDF

In this study, we aimed to assess the effects of enhanced external counterpulsation (EECP) and individual shear rate therapy (ISRT) on peripheral artery function in patients with lower extremity atherosclerotic disease (LEAD). We randomly assigned 45 LEAD patients to receive 35 sessions of 45 min of EECP (n = 15), ISRT (n = 15), or sham-control (n = 15). Flow-mediated dilation in the brachial artery (brachial-FMD); 6-min walk distance; blood flow in the popliteal, posterior tibial, anterior tibial, and dorsalis pedis arteries; and plasma levels were measured before and after the 7 weeks treatment.

View Article and Find Full Text PDF

Antegrade femoral puncture Using a Suture-Mediated Closure Device in infrainguinal endovascular interventions.

Ann Vasc Surg

December 2024

Department of Vascular Surgery, IRCCS Sacro Cuore-Don Calabria, Negrar, VR, Italy.

Introduction: ProGlide is a suture-mediated vascular closure device (VCD) indicated for retrograde access closure at the common femoral artery (CFA). However, its off-label use for antegrade and/or superficial femoral artery (SFA) access has become common in many practices. This study evaluated the efficacy and safety of ProGlide for femoral artery access closure in patients undergoing antegrade infrainguinal endovascular procedures.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!